$HIMS (+0,29%)

The FDA will discuss whether or not the GLP-1 "Tirzepatide" is still in short supply towards the end of the trading day tomorrow, after the Outsourcing Facilities Association took legal action against the FDA's decision to remove the weight loss drug from the shortage list. If the FDA were to declare the shortage over, many fear that Semaglutide will soon be removed from the list as well.